BCOR Sarcoma: Genetic Subtypes, Diagnosis, and Survival

BCOR sarcoma is not a single disease but a family of rare tumors linked by alterations in the BCOR gene, which encodes a protein called the BCL6 co-repressor. These tumors were only recognized as a distinct category in the last decade, and the 2020 WHO classification of soft tissue and bone tumors formally separated them from the broader bucket of “unclassified” sarcomas. Because BCOR alterations show up in several tumor types that look and behave quite differently from one another, the term can be confusing for patients and families encountering it for the first time.

What the BCOR Gene Normally Does

BCOR is part of a protein complex that acts as a kind of molecular gatekeeper in developing cells. In healthy human embryonic stem cells, the BCOR protein helps keep certain genes switched off, preventing cells from prematurely committing to become specific tissue types like bone, muscle, or gut lining. When researchers deplete BCOR from embryonic stem cells, those cells begin drifting toward endoderm and mesoderm fates, essentially losing their ability to stay in a flexible, undifferentiated state.¹ That role as a brake on differentiation helps explain why, when the BCOR gene breaks or fuses with another gene, the result can be uncontrolled growth of primitive-looking cells that never fully mature into normal tissue.

The Major Subtypes

Sarcomas with BCOR alterations fall into several molecular categories, each with its own clinical personality. The three you will encounter most often in the medical literature are BCOR::CCNB3 fusion sarcoma, BCOR internal tandem duplication (ITD) tumors, and ZC3H7B::BCOR fusion sarcoma.²

BCOR::CCNB3 Fusion Sarcoma

This was the subtype that put BCOR sarcoma on the map. Identified in 2012, it results from a rearrangement on the X chromosome that fuses the BCOR gene with CCNB3, a gene normally active only in the testes. The fusion protein drives cells into abnormal division. In the original discovery study, 24 positive cases were found among 594 sarcoma samples, and gene profiling showed these tumors were biologically distinct from Ewing sarcoma, the tumor they most closely resemble under the microscope.³ The 2020 WHO classification now lists BCOR::CCNB3 sarcoma as a genetically distinct subtype of undifferentiated small round cell sarcoma.⁴

BCOR Internal Tandem Duplication (ITD)

Instead of fusing with another gene, in some tumors a stretch of the BCOR gene’s own DNA gets duplicated and inserted back into itself. These internal tandem duplications cluster near the tail end of the protein and are the hallmark of clear cell sarcoma of the kidney (CCSK), the second most common kidney cancer in young children. In one study of 27 pediatric CCSK cases, roughly 85% carried BCOR ITDs.⁵ A separate series of 39 CCSK cases confirmed the dominance of this alteration, finding BCOR ITD in about 87% of tumors.⁶ BCOR ITDs also appear in soft tissue tumors outside the kidney, including primitive myxoid mesenchymal tumors of infancy and some undifferentiated round cell sarcomas.⁷

ZC3H7B::BCOR Fusion Sarcoma

This fusion is best known in high-grade endometrial stromal sarcomas of the uterus, but it occasionally turns up in soft tissue tumors at other body sites. One recent series described seven soft tissue tumors with ZC3H7B or ZC3H7A fused to BCOR, noting that these tumors often had a fibromyxoid appearance and overlapped with malignant ossifying fibromyxoid tumors.⁸ Soft tissue examples outside the uterus remain exceedingly rare.⁹

Who Is Affected

The demographics vary sharply by subtype. BCOR::CCNB3 sarcoma skews young and male. In the largest global collaborative study to date, the median age at diagnosis for BCOR::CCNB3 patients was 17 years, and boys and young men made up the majority of cases.¹⁰ A separate European multi-institutional analysis found the median age in the BCOR-rearranged soft tissue group was even younger, under a year old, though that cohort included infants with BCOR-ITD tumors.¹¹ The primary tumor sites are divided between bone and soft tissue: the abdomen, pelvis, and limbs are the most common locations.

BCOR-ITD clear cell sarcoma of the kidney, by contrast, is predominantly a disease of toddlers and very young children, consistent with the broader epidemiology of renal tumors in pediatrics. ZC3H7B::BCOR sarcomas tend to arise in adult women when they involve the uterus, though the rare soft tissue examples have been reported in both sexes.

What These Tumors Look Like Under the Microscope

Pathologists describe most BCOR-altered sarcomas as sheets of small, round to slightly spindle-shaped cells with uniform nuclei and fine chromatin, often laced with a delicate network of thin-walled blood vessels. Some tumors show a myxoid (mucus-like) or collagenous background stroma. A clinicopathologic study of 36 BCOR::CCNB3 cases noted this spectrum of round to spindle cells with variable cellularity and highlighted that the morphology overlaps considerably with other round cell sarcomas that upregulate BCOR, including BCOR-ITD tumors and BCOR-MAML3 fusion tumors.¹² Another series of 12 BCOR::CCNB3-positive tumors described round to epithelioid cells with oval to spindle-shaped nuclei set in a myxoid stroma with thin-walled intervening vessels.¹³

Because these features are shared with several other round cell sarcomas, morphology alone is usually not enough to make the diagnosis. That is where immunohistochemistry and molecular testing come in.

Getting the Diagnosis Right

The differential diagnosis for a small round cell sarcoma is long. Ewing sarcoma, the most common tumor in this morphological neighborhood, has to be considered first because it is far more frequent. Other contenders include CIC-rearranged sarcomas, desmoplastic small round cell tumor, mesenchymal chondrosarcoma, and in spindle cell-rich cases, infantile fibrosarcoma and synovial sarcoma.¹⁴ Distinguishing among these matters because treatment protocols and expected outcomes differ.

BCOR immunohistochemistry, which stains for the BCOR protein in tissue sections, is one of the first-line tools. Strong, diffuse nuclear BCOR staining is a sensitive marker for high-grade endometrial stromal sarcomas with YWHAE fusions and for tumors carrying BCOR rearrangements or ITDs.¹⁵ For BCOR::CCNB3 tumors specifically, CCNB3 immunohistochemistry serves as a practical screening test: in the original discovery series, CCNB3 staining was described as a powerful diagnostic marker because the CCNB3 protein is normally confined to testicular tissue and should not appear in sarcoma cells unless the fusion is present.¹⁶

Confirmation typically requires molecular testing, either fluorescence in situ hybridization (FISH) targeting the BCOR locus or next-generation sequencing approaches such as targeted RNA sequencing that can identify the specific fusion partner or ITD.

Diagnostic Pitfalls With BCOR Staining

A positive BCOR stain does not automatically mean BCOR sarcoma, and this is a real trap for the unwary. A study of Merkel cell carcinoma, a neuroendocrine skin cancer, found that up to 90% of Merkel cell tumors showed some degree of BCOR positivity. The same study tested small cell lung cancer and found diffuse, moderate-to-strong BCOR staining in every case examined.¹⁷ When a Merkel cell carcinoma presents as a mass mimicking a soft tissue or bone sarcoma, this false-positive BCOR staining could steer a pathologist down the wrong diagnostic path.

A similar issue exists in gynecologic pathology. Adenosarcoma, a mixed tumor of the uterus, can display diffuse BCOR expression in roughly 70% of cases. Because adenosarcoma can sometimes mimic high-grade endometrial stromal sarcoma with ZC3H7B::BCOR fusion, the presence of BCOR staining alone is not enough to distinguish between the two. Molecular confirmation of whether a BCOR or BCORL1 rearrangement is actually present becomes essential.¹⁸

Treatment Approaches

There is no consensus protocol specifically designed for BCOR sarcomas, and given the rarity of these tumors, one is unlikely to emerge from randomized trials any time soon. In practice, clinicians have borrowed regimens from Ewing sarcoma and osteosarcoma, both of which are better-studied bone and soft tissue cancers. The standard approach combines wide surgical resection with chemotherapy given before and/or after surgery, and radiation therapy is used liberally.¹⁹

Whether Ewing-type chemotherapy is better than other regimens remains an open and genuinely contentious question. Some groups have recommended Ewing sarcoma protocols, while others have pushed back. A meta-analysis of BCOR-rearranged sarcomas suggested that non-Ewing treatment was roughly equivalent to Ewing treatment, but that conclusion has been challenged because it pooled very different BCOR subtypes together, each with its own natural history and prognosis, in a small total sample.²⁰

Local recurrence after surgery has been reported at a rate of about 20% for BCOR::CCNB3 sarcoma, which is relatively high and may reflect the tumor’s tendency to grow in an infiltrative pattern, extending beyond what appears to be its borders on imaging or gross inspection.²¹

Survival and How It Compares

Among the undifferentiated small round cell sarcomas, BCOR::CCNB3 sarcoma has the most favorable prognosis. In the GRACefUl study, the largest global collaborative effort to compare these rare subtypes, the three-year overall survival for BCOR::CCNB3 patients was about 92%, compared to roughly 40% for CIC-rearranged sarcomas and 79% for unclassified undifferentiated round cell sarcomas. The difference was stark and statistically robust.²² BCOR::CCNB3 patients also had a lower rate of metastatic disease at diagnosis compared to their CIC-rearranged counterparts.

About 9 to 17% of BCOR::CCNB3 sarcoma patients have detectable metastases at diagnosis, depending on the study. For context, the rate for Ewing sarcoma is closer to 31%, lending support to the idea that BCOR::CCNB3 sarcoma presents in a less aggressive state than its closest clinical look-alike.²³ When metastases do occur, the lungs are the most common site, followed by bone, liver, pancreas, and other soft tissues.

BCOR-Altered Sarcomas in Infants

BCOR-ITD sarcomas occasionally arise in babies under a year old, and managing them presents unique challenges. In a small series of nine infants aged six weeks to 15 months, seven tumors carried BCOR ITDs and one had a BCOR::CCNB3 fusion. When upfront surgery was attempted and left residual disease behind, local progression followed quickly, within a median of about two and a half months. The infants who received chemotherapy using combinations such as vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide achieved complete responses on imaging. Seven of the nine patients also received radiation therapy. After a median follow-up of about two years off treatment, eight of the nine patients had no evidence of disease.²⁴

These early results are encouraging, but the numbers are tiny and long-term follow-up is still limited. For parents of an affected infant, the practical message is that incomplete surgery alone appears insufficient and that multimodal treatment with chemotherapy and radiation can produce durable remissions, at least in the short term.

What Imaging Reveals

Because BCOR sarcomas are so rare, radiologists have limited experience with their imaging signature. The available case series and reports generally describe an aggressive-appearing bone lesion accompanied by a large soft tissue mass, a pattern that is not specific and overlaps with Ewing sarcoma, osteosarcoma, and other primary bone tumors.²⁵ MRI typically shows the extent of the soft tissue component best, while CT and PET scans help with staging and detecting metastases. There are no imaging features reliable enough to distinguish BCOR sarcoma from Ewing sarcoma without biopsy, so a tissue sample remains essential.

Targeted Therapies and the Road Ahead

No targeted therapy has been approved or consistently effective for BCOR sarcomas so far. The sarcoma field has seen some progress with fusion-driven approaches in other tumor types: inhibitors targeting epigenetic regulators have been tried in synovial sarcoma, for instance, with modest activity in subsets of patients.²⁶ Because BCOR is itself an epigenetic regulator, similar strategies could theoretically apply, but this remains speculative. The immediate priority in the field is to refine chemotherapy regimens and test whether targeted approaches can add benefit.²⁷

One of the fundamental barriers is numbers. Even the largest published studies contain only a few dozen BCOR::CCNB3 cases, and the other subtypes are rarer still. International collaboration, like the GRACefUl consortium, is probably the only realistic path to generating enough data to support evidence-based treatment decisions. For patients diagnosed today, the practical reality is enrollment in a clinical trial or treatment based on expert consensus at a sarcoma referral center, borrowing protocols from better-studied diseases while the field slowly accumulates its own evidence base.

1
PubMed Central. A Non-canonical BCOR-PRC1.1 Complex Represses Differentiation Programs in Human ESCs ↩︎
2
PubMed Central. Soft Tissue and Visceral Organ Sarcomas With BCOR Alterations ↩︎
3
PubMed Central. A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion ↩︎
4
American Journal of Case Reports. Rare Case of BCOR::CCNB3 Sarcoma of Bone ↩︎
5
Nature Communications. Recurrent internal tandem duplications of BCOR in clear cell sarcoma of the kidney ↩︎
6
PubMed. Clinical relevance of BCOR internal tandem duplication and TP53 aberration in clear cell sarcoma of the kidney ↩︎
7
PubMed Central. Recurrent BCOR Internal Tandem Duplication and YWHAE-NUTM2B Fusions in Soft Tissue Undifferentiated Round Cell Sarcoma of Infancy ↩︎
8
PubMed Central. ZC3H7A/B::BCOR fusion fibromyxoid sarcoma of soft tissue ↩︎
9
PubMed. Soft tissue sarcoma with ZC3H7B::BCOR fusion in a male mimicking low-grade fibromyxoid sarcoma ↩︎
10
PubMed. A global collaborative study of CIC-rearranged, BCOR::CCNB3-rearranged and other ultra-rare unclassified undifferentiated small round cell sarcomas (GRACefUl) ↩︎
11
Cancer Medicine. Clinical characteristics and outcomes for children, adolescents and young adults with “CIC‐fused” or “BCOR‐rearranged” soft tissue sarcomas ↩︎
12
PubMed Central. BCOR-CCNB3 Fusion Positive Sarcomas: A Clinicopathologic and Molecular Analysis of 36 Cases ↩︎
13
International Journal of Surgical Pathology. Spectrum of Histopathological, Immunohistochemical, Molecular and Radiological Features in 12 Cases of BCOR::CCNB3-positive Sarcomas With Literature Review ↩︎
14
Diagnostic Pathology. Detection of BCOR gene rearrangement in Ewing-like sarcoma: an important diagnostic tool ↩︎
15
PubMed Central. BCOR is a robust diagnostic immunohistochemical marker of genetically diverse high-grade endometrial stromal sarcoma ↩︎
16
PubMed Central. A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion ↩︎
17
PubMed Central. Aberrant positivity for BCOR immunohistochemistry in merkel cell carcinoma ↩︎
18
PubMed Central. BCOR Expression in Mullerian Adenosarcoma: A Potential Diagnostic Pitfall ↩︎
19
Japanese Journal of Clinical Oncology. Update on the management of BCOR::CCNB3 sarcoma ↩︎
20
Japanese Journal of Clinical Oncology. Update on the management of BCOR::CCNB3 sarcoma ↩︎
21
Japanese Journal of Clinical Oncology. Update on the management of BCOR::CCNB3 sarcoma ↩︎
22
PubMed. A global collaborative study of CIC-rearranged, BCOR::CCNB3-rearranged and other ultra-rare unclassified undifferentiated small round cell sarcomas (GRACefUl) ↩︎
23
Japanese Journal of Clinical Oncology. Update on the management of BCOR::CCNB3 sarcoma ↩︎
24
PubMed Central. Strategies for the Treatment of Infantile Soft Tissue Sarcomas With BCOR Alterations ↩︎
25
PubMed. Imaging of bone and soft tissue BCOR-rearranged sarcoma ↩︎
26
The Cancer Review. Genomic and Multi-Omic Reclassification of Sarcomas: Implications for Diagnosis and Targeted Therapy ↩︎
27
Japanese Journal of Clinical Oncology. Update on the management of BCOR::CCNB3 sarcoma ↩︎